November 8, 2018 08:05 AM EST

InCarda grabs a $42M round to back PoC study for their inhaled cardio drug

John Carroll

Editor & Founder

San Francisco-based InCarda Therapeutics is taking a big step forward today, unveiling a $42 million B round after getting the company launched on a shoestring …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

InCarda grabs a $42M round to back PoC study for their inhaled cardio drug

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Stem cell startup spun out of George Church’s lab raises $75M

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Here's what today's Fed rate cut means for biotech, pharma and venture capital

Upstream Bio files for IPO in sign of life for biotech public offerings

Edgewise’s stock surges as heart drug passes early safety test

Breaking down silos with a new quantitative approach to drug development

In­Car­da grabs a $42M round to back PoC study for their in­haled car­dio drug

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

InCarda grabs a $42M round to back PoC study for their inhaled cardio drug